ReviewDermatology and therapy2023
Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?
Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Contemporary management of treatment-related dermatologic toxicities in gynecologic cancers: a systematic review based on evidence from 2021 to 2025.Frontiers in medicine · 2026Pooled it
- Gnotobiology: from 19th-century global foundations to 21st-century omics - six decades of Czech contribution to microbiome research.Folia microbiologica · 2026Review
- Immunoprotective and neuroprotective properties of gut microbiome in psoriasis.Journal of translational autoimmunity · 2026Review
- Correlation between IL-17 levels and chronic urticaria: Systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2026Article
- Interaction of Ferroptosis and Immune-Mediated Inflammation in Psoriasis.Antioxidants (Basel, Switzerland) · 2026Review
- Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.Life (Basel, Switzerland) · 2026Review
- Mechanistic insights into how gut homeostasis and immune-system crosstalk shape ankylosing spondylitis.Frontiers in immunology · 2026Review
- Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of Crohn's disease with concomitant psoriasis.EBioMedicine · 2025Article
- Role of gut microbiota in the development of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Topical Probiotics as a Novel Approach in the Treatment of Chronic Dermatoses Associated with Skin Dysbiosis: A Narrative Review.International journal of molecular sciences · 2025Review
- Case Report: Treating one autoimmune disease induces another: the paradox of TNF-alpha inhibitor therapies.Frontiers in immunology · 2025Article
- Exploring the Shared Diagnostic Genes in IBD and Psoriasis through Bioinformatics and Experimental Assays.International journal of medical sciences · 2025Article
- Engineered Delivery Systems for Chinese Herbal Medicine in Peripheral Nerve Regeneration: Challenges, Advances, and Future Perspectives.Drug design, development and therapy · 2025Review
- Plasma Cytokines for the Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis.Journal of clinical medicine · 2024Article
- Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors.International journal of molecular sciences · 2024Review
- Hsa-miR-877-5p Expression in Acute Ischemic Stroke Based on Bioinformatics Analysis and Clinical Validation.Molecular neurobiology · 2024Article
- Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.Frontiers in immunology · 2024Review
- Psoriasis and gut microbiota: A Mendelian randomization study.Journal of cellular and molecular medicine · 2024Article
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- Perspective to precision medicine in scleroderma.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Psoriasis is a chronic, immune-mediated, inflammatory disease primarily affecting the skin. It is currently coming to light that patients with psoriasis have disrupted intestinal barrier and often suffer from comorbidities associated with the gastrointestinal tract. Moreover, there is growing evidence of both cutaneous and intestinal paradoxical reactions during biologic treatment in patients with psoriasis. This review focuses on barrier defects and changes in immune responses in patients with psoriasis, which play an important role in the development of the disease but are also influenced by modern biological treatments targeting IL-17 and TNFα cytokines. Here, we highlight the relationship between the gut-skin axis, microbiota, psoriasis treatment, and the incidence of paradoxical reactions, such as inflammatory bowel disease in patients with psoriasis. A better understanding of the interconnection of these mechanisms could lead to a more personalized therapy and lower the incidence of treatment side effects, thereby improving the quality of life of the affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.